Anti-Bevacizumab Antibody (11C1), mAb, Mouse

Cat. No.: A02185

Overview

Specificity	The product is specific for Bevacizumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody MonoRab™ Anti-Bevacizumab Antibody (46E3), mAb, Rabbit (GenScript, A01962) or MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit (GenScript, A01896) .
Host Species	Mouse
Immunogen	Bevacizumab
Conjugate	Unconjugated

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Application	Recommended Usage
ELISA	0.01-0.1 µg/ml
Chemiluminescent immunoassay (CLIA)	0.5-2 µg/ml

Properties

Form	Lyophilized
Storage Buffer	Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable up to 1 year at -20°C from date of receipt. The reconstituted antibody can be stored for 2-3 weeks at 2-8°C. For long term storage, aliquot and store at -20°C or below. Avoid repeated freezing and thawing cycles.

Purification	Purified by Protein A affinity chromatography
Isotype	Mouse IgG1, κ
Clonality	Monoclonal
Clone ID	11C1
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples

**Anti-Bevacizumab Antibody (11C1) binds with Bevacizumab**

Figure 1. ELISA binding of Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) with Bevacizumab. While the antibody does not recognize the human IgG (data not shown).

Coating antigen: Bevacizumab, 1 µg/ml.

Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) dilution start from 1,000 ng/ml.

**Standard Curve of Bevacizumab Sandwich CLIA**

Figure 2. Standard curve of Bevacizumab Sandwich CLIA (Chemiluminescent immunoassay).

The Bevacizumab Sandwich CLIA assay is developed by using Anti-Bevacizumab Antibody (11C1), mAb, Mouse (GenScript, A02185) and MonoRab™ Anti-Bevacizumab Antibody (46E3) [Biotin], mAb, Rabbit (GenScript, A01896) as the capture and detection antibodies, respectively.

Capture antibody: Anti-Bevacizumab Antibody (11C1), mAb, Mouse, 1.5 µg/ml

Detection antibody: MonoRab™ Anti-Bevacizumab Antibody (46E3)[Biotin], mAb, Rabbit, 0.5 µg/ml

Background

Target Background : Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of a number of types of cancers and a specific eye disease. Bevacizumab binds to a continuous epitope in VEGF, preventing the interaction of VEGF with VEGFR on the surface of endothelial cells. It can be used to inhibit solid tumour growth and metastasis by weakening tumour angiogenesis.

Synonyms : Avastin

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.